← Back to Search

Reading Education Program for Dyslexia

N/A

Waitlist Available

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Must not have

No major contraindication for MRI (braces, metal implants, pacemakers, vascular stents, or metallic ear tubes)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change between baseline (within 2 weeks pre-intervention) and post-intervention (within 2 weeks post-intervention)

Awards & highlights

No Placebo-Only Group

Summary

This trial will use neuroimaging and reading education programs to study how the brain develops in children with dyslexia, in order to improve treatment methods.

Who is the study for?

This trial is for children with dyslexia, which means they have trouble reading accurately or fluently. They must be native English speakers without braces, metal implants, pacemakers, stents, or metallic ear tubes that would interfere with MRI scans. They should not have neurological disorders or significant psychiatric problems and cannot be claustrophobic.

What is being tested?

The study tests the 'Lindamood-Bell Seeing Stars' program to see how it affects brain development related to reading skills in children with dyslexia. It uses advanced neuroimaging methods to understand individual learning differences and aims at personalizing dyslexia treatment.

What are the potential side effects?

Since this intervention involves educational programs rather than medication, traditional side effects are not expected. However, participants may experience discomfort from sitting still during MRI scans or stress related to testing environments.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I don't have metal implants, braces, pacemakers, stents, or ear tubes that prevent MRI.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change between baseline (within 2 weeks pre-intervention) and post-intervention (within 2 weeks post-intervention)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change between baseline (within 2 weeks pre-intervention) and post-intervention (within 2 weeks post-intervention)

This trial's timeline: 3 weeks for screening, Varies for treatment, and change between baseline (within 2 weeks pre-intervention) and post-intervention (within 2 weeks post-intervention) for reporting.